Intramuscular depomedroxyprogesterone acetate for contraception.

Suporn Koetsawang, S Srisuphandit, S Srivanaboon, P Bhiráleus, D Rachawat, O Kiriwat, A Koetsawang

PubMed · 1974 · 15 citations · 0 references

Concepts

Abstract

The feasibility of using a long-acting injectable contraceptive in family planning programs in Thailand was assessed based on data from 886 women and 24399 woman-months of therapy. The participants were healthy women aged 25 or over from low socioeconomic groups having 2 or more children. They were informed that an unpredictable menstrual pattern would result. Later women under age 25 with 1 or more children were also accepted. Only 38% had previously used contraception. Most accepted because they desired no more children. Depomedroxyprogesterone acetate (DMPA) 150 mg was administered im every 90 days. 201 (22.7%) were lost to follow-up. At the cutoff date of the study there had been 513 dropouts and 373 continuing the method. After 4 years only a few continued. During the medication period 25 women became pregnant a rate of 1.2/100 woman-years. In 50 patients injections had been delayed 2-4 weeks. Most conception dates were within the last 14 days of the postinjection period. All had received 1 injection before pregnancy was recognized. 23 of the 25 delivered healthy children at term. 1 aborted at 6 months and 1 was still pregnant. 174 women changed to another method. Abnormal menstrual patterns were the most frequent medical reason. A majority had no other complaints. There were no serious complications. 74 chose oral contraceptives. 41 had interval tubal sterilization. Husbands of 6 had vasectomies. IUDs were used by 25. Courses of oral contraceptives were given to a few to cycle menstrual bleeding while injections were continued. Increased weight was recorded by 62.8% after 48 months. Various laboratory tests in 200 cases studied after 2-3 years of medication were all normal. Cervical dysplasia was detected in 2 and carcinoma in situ in 1. After 12 months or more of therapy the endometrium became quiescent or atrophic in many. Ovarian biopsies performed in 6 cases after 6 or more injections showed small fibrotic ovaries. No corpora lutea were observed. 28 of 29 patients who wished to become pregnant after discontinuing therapy did so within 18 months. 24 delivered a full-term healthy infant 1 aborted at 8 weeks gestation and 3 were still pregnant at the end of the study period. As delayed ovulation may occur after this therapy it is advised that DMPA users who wish to become pregnant should discontinue this method about 1 year before they plan pregnancy. The method was well accepted and is recommended as an addition to the family planning program in Thailand. Shortening the interval between injections to 80-84 days would probably avoid most of the few unplanned pregnancies.